No discrete molecular target

Class

allogeneic gamma-delta (γδ) T-cell therapy, combined with low-dose radiotherapy

Pathway

innate-like γδ T-cell-mediated tumor cytotoxicity, primed by localized low-dose radiation

Notes

original target text: not a molecular receptor target -- allogeneic donor-derived cell product

This therapy is not built around a single molecular receptor or enzyme. Instead, it uses an entire immune cell type—gamma-delta (γδ) T cells—manufactured from a donor (allogeneic) rather than the patient, and delivered alongside localized low-dose radiotherapy to the tumor site. γδ T cells are a minority subset of T lymphocytes that recognize stressed or transformed cells through mechanisms that do not require matching the patient's own tissue markers (major histocompatibility complex, or MHC), unlike conventional T cells. This property makes them naturally suited to an 'off-the-shelf' allogeneic product, since they carry lower risk of attacking healthy host tissue or being rapidly rejected. Low-dose radiation is used not to directly kill the tumor but to alter it biologically: radiation-stressed tumor cells display more of the molecular flags that γδ T cells detect, and radiation can also loosen the local immunosuppressive environment that otherwise shields tumors from immune attack. Combining a donor-derived innate-like effector cell with a radiation 'priming' step is a strategy relevant across solid tumor types where immune cells struggle to recognize and penetrate tumor tissue. The general rationale extends to broader efforts in cellular immuno-oncology and combination approaches pairing cell therapies with conventional oncologic modalities.